BOJI MEDICAL TECHNOLOGY CO.,LTD. Boji Medical Technology Co.,Ltd. Share Price
Equities
300404
CNE100001Y00
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.31 CNY | +0.55% |
|
+9.76% | -18.32% |
| Sales 2022 | 424M 58.47M 4.88B | Sales 2023 | 556M 76.71M 6.4B | Capitalization | 3.42B 472M 39.34B |
|---|---|---|---|---|---|
| Net income 2022 | 27M 3.73M 311M | Net income 2023 | 24M 3.31M 276M | EV / Sales 2022 | 6.16 x |
| Net cash position 2022 | 272M 37.51M 3.13B | Net cash position 2023 | 293M 40.43M 3.37B | EV / Sales 2023 | 5.62 x |
| P/E ratio 2022 |
104
x | P/E ratio 2023 |
136
x | Employees | 1,186 |
| Yield 2022 |
0.13% | Yield 2023 |
-
| Free-Float | 58.86% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.55% | ||
| 1 week | +9.76% | ||
| Current month | -3.69% | ||
| 1 month | -2.01% | ||
| 3 months | -4.69% | ||
| 6 months | -17.87% | ||
| Current year | -18.32% |
1 week
6.56
7.63
1 month
6.277.89
Current year
5.039.17
1 year
5.0312.88
3 years
5.0312.88
5 years
5.0314.43
10 years
3.5942.43
| Managers | Title | Age | Since |
|---|---|---|---|
Ting Cun Wang
CEO | Chief Executive Officer | 59 | 11/11/11 |
Xiu Qing Ou
DFI | Director of Finance/CFO | 42 | 01/03/01 |
Bo Tan
BRD | Director/Board Member | 42 | 01/05/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ting Cun Wang
CEO | Chief Executive Officer | 59 | 11/11/11 |
Yu Ping Han
PRN | Corporate Officer/Principal | 51 | 01/08/01 |
Bo Tan
BRD | Director/Board Member | 42 | 01/05/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 7.31 | +0.55% | 11,867,410 |
| 25/24/25 | 7.27 | +4.15% | 15,433,440 |
| 24/24/24 | 6.98 | +1.90% | 5,339,017 |
| 23/24/23 | 6.85 | +1.48% | 5,612,810 |
| 22/24/22 | 6.75 | +1.35% | 4,463,566 |
End-of-day quote Shenzhen S.E., April 26, 2024
More quotes
Boji Medical Technology Co Ltd is a China-based company that provides Contract Research Organization (CRO) services. The Company mainly provides one-stop CRO services for the development and production of new drugs and medical devices for domestic and foreign pharmaceutical companies and other research institutions. The Company's CRO services include pre-clinical research services, clinical research services, other consulting services, pharmaceutical Contract Development Manufacture Organization (CDMO) services, pre-clinical independent research and development services, and technology achievement transformation services. The Company mainly conducts its businesses in the domestic market.
Calendar
16/05/2024
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.32% | 385M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- 300404 Stock
